Hap Trading, LLC Sarepta Therapeutics, Inc. Transaction History

Hap Trading, LLC

$1.06 Trillion
Q2 2025

A detailed history of Hap Trading, LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Hap Trading, LLC holds 16,000 shares of SRPT stock, worth $300,960. This represents 0.05% of its overall portfolio holdings.

Number of Shares

16,000

Holding current value

$300,960

% of portfolio

0.05%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $3.41 Million - $4.92 Million	30,054 Added 272.65%	41,077 $6.49 Billion
Q1 2024 May 13, 2024	BUY	$93.7 - $141.53 $1.03 Million - $1.56 Million	11,023 New	11,023 $1.43 Billion
Q1 2021 May 14, 2021	SELL	$72.25 - $168.95 $31,862 - $74,506	-441 Reduced 4.15%	10,182 $759,000
Q4 2020 Feb 16, 2021	SELL	$125.56 - $178.74 $5 Million - $7.12 Million	-39,843 Reduced 78.95%	10,623 $1.81 Million
Q2 2019 Aug 14, 2019	BUY	$112.21 - $151.95 $3.95 Million - $5.34 Million	35,172 Added 229.97%	50,466 $7.67 Million
Q4 2018 Feb 12, 2019	SELL	$97.32 - $148.76 $234,443 - $358,362	-2,409 Reduced 13.61%	15,294 $1.67 Million
Q3 2018 Nov 09, 2018	BUY	$115.31 - $161.51 $2.04 Million - $2.86 Million	17,703 New	17,703 $2.86 Million

Others Institutions Holding SRPT

# of Institutions

412

Shares Held

153M

Call Options Held

5.44M

Put Options Held

6.09M

Paul Tudor Jones Tudor Investment Corp Et Al | Stamford, Ct

68.8M
Shares

$1.29 Billion
0.66% of portfolio
Vanguard Group Inc Valley Forge, PA

10.8M
Shares

$203 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.3M
Shares

$194 Million
0.04% of portfolio
State Street Corp Boston, MA

5.3M
Shares

$99.8 Million
0.0% of portfolio
Erste Asset Management Gmb H Vienna, C4

2.69M
Shares

$50.5 Million
0.49% of portfolio

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $1.65B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.

Account